ASCP SBB common mistakes
ASCP SBB · Understand the traps and how to avoid them.
On antibody identification panels, calling a specificity from the first pattern that fits instead of formally ruling out every other antibody using homozygous (dosage) cells and selected-cell testing.
Candidates rely on visual pattern recognition under time pressure and forget that rule-out requires at least two or three antigen-positive, antibody-negative cells, plus consideration of dosage, enzyme sensitivity, and high-frequency antigens.
What to do instead
Use a written rule-out grid for every panel: record antigen zygosity, exclude each specificity with documented cells, and repeat with enzyme-treated or selected cells before finalizing; perform adsorption/elution when the pattern is inconsistent.
Classifying every weak D reaction as D-positive (or every one as D-negative) and selecting units without distinguishing weak D types 1, 2, 3 from partial D variants.
Tube/gel weak D testing is taught as a single step, and candidates do not connect serologic weak D phenotype to the molecular weak D type and its transfusion implications.
What to do instead
Memorize the policy framework: weak D types 1, 2, and 3 may be managed as D-positive for transfusion, while partial D and unknown weak D types are managed as D-negative; use RHD genotyping when the phenotype is ambiguous.
Applying the wrong storage or expiration rule to a processed component, such as labeling thawed plasma as a 24-hour product when it is stored at 1–6°C, or freezing plasma after the 8-hour/24-hour window without recognizing the product definition.
Component processing rules are learned as isolated facts, and candidates confuse FFP (frozen within 8 hours), FP24, thawed plasma (5 days at 1–6°C), and cryoprecipitate or platelet storage limits.
What to do instead
Build a one-page component table listing collection-to-freezing time, storage temperature, expiration after thawing, and open-system versus closed-system changes; drill it by writing the table from memory before each study session.
Choosing transfusion triggers by hemoglobin number alone, without applying the restrictive threshold to the correct clinical setting and without recognizing when a patient is stable enough to wait.
Candidates memorize a single hemoglobin value and then over-apply it to bleeding, cardiac, or obstetric patients, or they ignore the evidence base behind patient blood management.
What to do instead
Study the guideline thresholds as clinical scenarios: restrictive transfusion at approximately 7 g/dL for most stable hospitalized adults, with recognized exceptions; practice by writing the indication, threshold, and alternative therapy for each scenario.
Closing a quality event by writing a corrective action without identifying the root cause, and accepting a proficiency-testing or QC failure as an isolated error.
Candidates focus on the immediate fix and skip the causal analysis, so they miss the exam's emphasis on root cause analysis, CAPA linkage, and documentation of effectiveness checks.
What to do instead
For every QC or PT failure, write the full chain: containment, root cause (using a structured method such as five-whys or fishbone), corrective action, preventive action, and effectiveness verification; practice mapping each step to the SOP and regulatory requirement.
Reporting a transfusion fatality only to the hospital's internal quality system or only to AABB, rather than to FDA as required, and missing the required timelines.
Candidates conflate accreditation standards with FDA regulations and do not separate the initial notification from the written follow-up report.
What to do instead
Memorize the FDA fatality-reporting pathway: initial notification to FDA as soon as possible (by phone or email) and a written report within the regulatory timeframe; distinguish this from AABB and state reporting obligations, and write out the sequence from memory.
Using molecular red cell genotyping as a replacement for serologic phenotyping without recognizing when genotype and phenotype can diverge, such as in RH variants, mixed-field chimerism, or recent transfusion.
Candidates treat genotyping as a definitive answer and forget that silencing mutations, hybrid RHD alleles, and mixed cell populations can produce a genotype that does not match the expressed antigen.
What to do instead
State the limitation before the result: compare genotype with current and historical serology, consider transfusion history and chimerism, and confirm unexpected discordance with absorption/elution or additional molecular testing.
Accepting a cellular therapy product for infusion without independently verifying the ISBT 128 label, identity match, temperature, and expiration, and without checking for clumping or container integrity.
Candidates focus on the CD34 dose or viability number and treat the label and physical inspection as clerical steps rather than the last safety barrier.
What to do instead
Practice a mock bedside/product-release check: two identifiers, label-to-order match, ISBT 128 product code, temperature indicator, expiration, container integrity, and visual inspection; document each element in order.
Proceeding with pretransfusion testing when an ABO discrepancy is unresolved, or using an electronic crossmatch for a patient who does not meet the eligibility criteria.
Candidates want to complete the crossmatch and treat discrepancies as nuisance findings, forgetting that unresolved ABO discrepancies and electronic crossmatch eligibility are hard stops.
What to do instead
Write and rehearse the ABO discrepancy algorithm: repeat testing, check historical blood type, test a new sample, resolve with adsorption/elution if needed; list the electronic crossmatch eligibility criteria (two concordant ABO types, no history of discrepancy, validated system) before selecting units.
Answering regulatory or standards questions from general memory instead of distinguishing which body requires what, such as FDA versus AABB versus CAP versus FACT.
The exam deliberately tests overlapping requirements, and candidates memorize a single rule without attaching it to its source and scope.
What to do instead
Create a source matrix with columns for FDA, AABB, CAP, and FACT and rows for the major topics (donor screening, component labeling, QC, proficiency testing, cellular therapy); fill it from primary standards and review the matrix weekly.